Unique ID issued by UMIN | UMIN000043162 |
---|---|
Receipt number | R000049265 |
Scientific Title | Preoperative less painful mechanical bowel preparation in elective resection colorectal cancer surgery: a multicenter randomized non-Inferiority study |
Date of disclosure of the study information | 2021/01/28 |
Last modified on | 2023/08/02 21:00:02 |
Preoperative less painful mechanical bowel preparation in elective resection colorectal cancer surgery: a multicenter randomized non-Inferiority study
Preoperative less painful mechanical bowel preparation in elective resection colorectal cancer surgery: a multicenter randomized non-Inferiority study
Preoperative less painful mechanical bowel preparation in elective resection colorectal cancer surgery: a multicenter randomized non-Inferiority study
Preoperative less painful mechanical bowel preparation in elective resection colorectal cancer surgery: a multicenter randomized non-Inferiority study
Japan |
left colon cancer, rectal cancer
Gastrointestinal surgery |
Malignancy
NO
For all patients undergoing intestinal anastomosis in left-sided colon and rectal cancer surgery, the purpose of this study is to show that a less painful preoperative oral antibiotics and mechanical bowel preparation (mOAMBP (1 day method: 75.0 mg of sodium picosulfate hydrate the day before surgery, or 2 days method: 37.5 mg two days before surgery and 37.5 mg the day before surgery)) is non-inferior to the conventional preoperative oral antibiotics and mechanical bowel preparation (OAMBP (1 day method: 1 pack of PEG based solution the day before surgery, or 2 days method: 1 pack of PEG based solution two days before surgery)) in the incidence of postoperative complications.
Efficacy
Confirmatory
Pragmatic
Not applicable
Incidence of SSI
Incidence of postoperative complications excluded SSI, operation time, extent of bleeding, postoperative hospital stay, intraoperative adverse events, degree of patient burden, degree of intraoperative intestinal dilation
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
YES
Institution is considered as adjustment factor in dynamic allocation.
NO
Central registration
2
Treatment
Medicine |
mOAMBP group(sodium picosulfate hydrate + Kanamycin, Metronidazole)
(combined drug)
Kanamycin 250mg 12C x3(after lunch, dinner, and before bedtime) and Metronidazole 250mg 6C x3(after lunch, dinner, and before bedtime) per oral the day before surgery
(research drug)
(1 day method) sodium picosulfate hydrate 75.0mg(after hospitalization) per oral
or
(2 days method) sodium picosulfate hydrate 37.5 mg two days before surgery(after hospitalization) and 37.5 mg the day before surgery(morning) per oral
OAMBP group(PEG/PEG based solution + Kanamycin, Metronidazole)
(combined drug)
Kanamycin 250mg 12C x3(after lunch, dinner, and before bedtime) and Metronidazole 250mg 6C x3(after lunch, dinner, and before bedtime) per oral the day before surgery
(control drug)
(1 day method) 1 pack of PEG/ PEG based solution the day before surgery(after hospitalization) per oral
(2 days method) 1 pack of PEG/ PEG based solution two days before surgery(after hospitalization) per oral
20 | years-old | <= |
85 | years-old | > |
Male and Female
1) Patients undergoing resection for rectal cancer or left-sided colon cancer, with or without diverting ileostomy
2) Patients undergoing DST or transanal bowel anastomosis
3) Patients between 20 and 85 years old
4) Patients with a performance status (ECOG) of 0 or 1
5) Patients who meet the following criteria for laboratory tests within 30 days of enrollment
1. White blood cell: WBC = 3000, or 3000<WBC<10000/ul
2. Neutrophils: Neu = 1500, Neu > 1500/ul
3. Hemoglobin: Hb = 9.0 or > 9.0g/dl
4. Platelet: Plt = 70000 or > 70000/ul
5. Total Bilirubin: T.Bil = 1.5 or < 1.5mg/dl
6. AST: AST = 100 or < 100IU/l
7. ALT: ALT = 100 or < 100IU/l
8. Albumin: Alb = 2.5 or > 2.5g/dl
6) Patients who have given informed consent
1) Patients who need emergency surgery
2) Patients with preoperative intestinal obstruction
3) Patients with suspected active bacterial infection (abscess formation, colon cancer perforation, etc.)
4) Patients who are pregnant or have the potential to become pregnant
5) Diabetic patients with poor control (HbA1c 8.0 or < 8.0)
6) Patients who are allergic to drugs used in the study (macrogol, sodium picosulfate hydrate, kanamycin, metronidazole)
7) Patients undergoing neoadjuvant radiotherapy or neoadjuvant chemotherapy
8) Patients with colostomy or ileostomy
9) Patients who have not given informed consent
10) Patients who are judged by the principal investigator or the investigator to be ineligible for the safe conduct of this study
108
1st name | Yusuke |
Middle name | |
Last name | Kinugasa |
Tokyo Medical and Dental University Graduate School of Medicine
Department of Gastrointestinal Surgery
113-8519
1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan
03-5803-5254
kinugasa.srg1@tmd.ac.jp
1st name | Sodai |
Middle name | |
Last name | Arai |
Tokyo Medical and Dental University Graduate School of Medicine
Department of Gastrointestinal Surgery
113-8519
1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan
03-5803-5254
sarai.srg1@tmd.ac.jp
Tokyo Medical and Dental University Graduate School of Medicine
none
Self funding
Tokyo Medical and Dental University Ethics Review Committee
1-5-45 Yushima, Bunkyo-ku, Tokyo
03-5803-6111
syomu1.adm@tmd.ac.jp
NO
東京医科歯科大学医学部付属病院(東京都)、江戸川病院(東京都)
2021 | Year | 01 | Month | 28 | Day |
Unpublished
119
Completed
2021 | Year | 01 | Month | 01 | Day |
2021 | Year | 02 | Month | 18 | Day |
2021 | Year | 04 | Month | 01 | Day |
2023 | Year | 03 | Month | 31 | Day |
2021 | Year | 01 | Month | 28 | Day |
2023 | Year | 08 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049265